Degree of nephrotoxicity after intermediate‐ or high‐dose cisplatin‐based chemoradiotherapy in patients with locally advanced head and neck cancer
C.M.L. Driessen(Radboud University Nijmegen), Carla M.L. van Herpen(Radboud University Nijmegen), Claudia C. M. van Opstal(Radboud University Nijmegen), Winette T.A. van der Graaf(The Netherlands Cancer Institute), J.H.A.M. Kaanders(Radboud University Medical Center), Maike J.M. Uijen(Radboud University Nijmegen), Tom Nijenhuis(Radboud University Nijmegen)
Cited by 22
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia
|Journal of Clinical Investigation|2005|489
Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement
|International Journal of Radiation Oncology*Biology*Physics|2020|211